dehydroepiandrosterone has been researched along with Hyperandrogenism in 92 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Hyperandrogenism: A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 9.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "Hyperandrogenaemia in polycystic ovary syndrome (PCOS) represents a composite of raised serum concentrations of testosterone, androstenedione, dehydroepiandrosterone (DHEA) and DHEA sulphate (DHEAS)." | 9.16 | Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. ( Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Smith, KA, 2012) |
| "Inflammation is involved in the progression of polycystic ovary syndrome." | 5.91 | Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue†. ( Ding, X; Li, G; Li, N; Lin, Y; Ma, Y; Wang, X; Xiong, C; Yang, Y; Yuan, Y; Zhang, Y; Zhang, Z, 2023) |
| "Hyperandrogenism is the hallmark of polycystic ovary syndrome (PCOS)." | 5.48 | The use of dehydroepiandrosterone-treated rats is not a good animal model for the study of metabolic abnormalities in polycystic ovary syndrome. ( Ho, LT; Huang, SW; Juan, CC; Seow, KM; Ting, CH, 2018) |
| "Non-classic congenital adrenal hyperplasia (NC-CAH), one of the most common genetic disorders, is often associated with the clinical features of hyperandrogenism." | 5.40 | The effect of metformin on androgen production in diabetic women with non-classic congenital adrenal hyperplasia. ( Krysiak, R; Okopien, B, 2014) |
| "Treatment with metformin or rosiglitazone prevents excess adrenal androgen synthesis." | 5.34 | Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. ( Bahtiyar, G; Sacerdote, AS; Weiss, K, 2007) |
| "Dehydroepiandrosterone production was increased by atRA and 9-cis RA in normal cells and by atRA, 9-cis RA, and retinol in PCOS." | 5.33 | Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome. ( Hendricks, KL; Legro, RS; McAllister, JM; Nelson-DeGrave, VL; Strauss, JF; Wickenheisser, JK, 2005) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 5.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "Hyperandrogenaemia in polycystic ovary syndrome (PCOS) represents a composite of raised serum concentrations of testosterone, androstenedione, dehydroepiandrosterone (DHEA) and DHEA sulphate (DHEAS)." | 5.16 | Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. ( Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Smith, KA, 2012) |
| " We report 15 patients with adrenal hyperandrogenism and elevated levels of dehydroepiandrosterone sulfate that received treatment with dexamethasone." | 5.08 | [Prolonged remission of female hyperandrogenism after discontinuing glucocorticoid therapy]. ( Aravena, L; Devoto, E; Gaete, X, 1995) |
| " Observational studies do not support the hypothesis that dehydroepiandrosterone sulfate deficiency is a risk factor for coronary artery disease." | 4.82 | Androgens and coronary artery disease. ( von Eckardstein, A; Wu, FC, 2003) |
| "We used dehydroepiandrosterone (DHEA)-induced PCOS-like rat model to measure circadian clock genes and insulin resistance-related genes." | 3.96 | Decreased brain and muscle ARNT-like protein 1 expression mediated the contribution of hyperandrogenism to insulin resistance in polycystic ovary syndrome. ( Di, F; Du, Y; Hu, M; Li, S; Liu, J; Zhai, J, 2020) |
| "Female prepubertal rats were treated with equine chorionic gonadotropin (eCG) to induce folliculogenesis, together with dehydroepiandrosterone (DHEA) to induce hyperandrogenism and/or PGZ to evaluate PPARG activation." | 3.91 | Treatment with the synthetic PPARG ligand pioglitazone ameliorates early ovarian alterations induced by dehydroepiandrosterone in prepubertal rats. ( Abruzzese, GA; Ferreira, SR; Heber, MF; Motta, AB; Velez, LM, 2019) |
| "The objective of this study was to investigate the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ) in adipose tissue of the rat model of polycystic ovary syndrome (PCOS), induced by dehydroepiandrosterone (DHEA)." | 3.80 | Expression of PPAR-γ in adipose tissue of rats with polycystic ovary syndrome induced by DHEA. ( Wang, YX; Xie, BG; Zhu, WJ, 2014) |
| "Because of the elevated dehydroepiandrosterone sulfate (DHEAS) levels in polycystic ovary syndrome (PCOS) and the heritability of DHEAS serum levels, genes encoding the enzymes that control the sulfation of dehydroepiandrosterone (DHEA) to DHEAS and vice versa are obvious candidate genes to explain part of the heritability of PCOS." | 3.79 | Variants in SULT2A1 affect the DHEA sulphate to DHEA ratio in patients with polycystic ovary syndrome but not the hyperandrogenic phenotype. ( de Jong, FH; Fauser, BC; Laven, JS; Louwers, YV; Stolk, L; Uitterlinden, AG; van Herwaarden, NA, 2013) |
| "We evaluated the effect of hyperandrogenism in ovaries with functional and regressing corpora lutea (CL) and the action of metformin in preventing these possible alterations using a mouse model." | 3.75 | Effect of DHEA and metformin on corpus luteum in mice. ( Facorro, GB; Motta, AB; Piehl, L; Rubín de Celis, E; Sander, VA, 2009) |
| "Measured endocrinological parameters (total testosterone [TT], free testosterone [FT], dihydrotestosterone [DHT], dehydroepiandrosterone sulfate [DHEAS], and sex hormone binding globulin [SHBG]) and calculated parameters (calculated FT (cFT), calculated bioavailable testosterone (cBT), and the free androgen index [FAI]) in women with hirsutism were compared to the values of a control group." | 3.74 | Endocrinological markers for assessment of hyperandrogenemia in hirsute women. ( Beckmann, MW; Binder, H; Cupisti, S; Dittrich, R; Hoffmann, I; Kiesewetter, F; Mueller, A, 2007) |
| " Anthropometric measurements, staging of pubertal maturation, and clinical manifestations of hyperandrogenism were assessed, as well as measurement of serum levels of testosterone, dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG), and free androgen index (FAI)." | 3.72 | Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy. ( Abd El-Basset, FZ; El Barbary, NS; El-Khayat, HA; Hakky, SM; Mohamed, MS; Nassef, NM; Tohamy, SM; Tomoum, HY; Zaky, AA, 2004) |
| " The biochemical marker for functional ovarian hyperandrogenism was the 17-hydroxyprogesterone (17-OHP), androstenedione (AD), and estradiol (E2) response to subcutaneous leuprolide during adrenal suppression with dexamethasone." | 3.71 | Premature pubarche in girls is associated with functional adrenal but not ovarian hyperandrogenism. ( Lorenz, RA; Mathew, RP; Mayes, DE; Najjar, JL; Russell, WE, 2002) |
| "To evaluate the relative or discriminatory usefulness of sex hormone binding globulin (SHBG), dehydroepiandrosterone sulphate (DHEAS) and insulin like growth factor binding protein 1 (IGFBP-1) as markers of insulin resistance and to estimate the tissue sensitivity to insulin by means of the insulin tolerance test (ITT) and the frequently sampled i." | 3.69 | [Biochemical markers and methods to assess insulin resistance in normal, obese and hyperandrogenic women]. ( Calvillán, M; Castillo, T; Durruty, P; López, G; Muñoz, S; Sir, T, 1997) |
| "For dose-response studies, blood samples were obtained before and at 0." | 2.76 | Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome. ( Chang, RJ; Coffler, MS; Donohue, MC; Duke, KB; Haggan, A; Rosencrantz, MA; Shayya, RF; Su, HI, 2011) |
| "As insulin resistance is an underlying feature of premature adrenarche, it seems rational to assess the efficacy and safety of using insulin-sensitizing agents to treat these individuals." | 2.41 | Premature adrenarche. ( Dimartino-Nardi, J; Saenger, P, 2001) |
| "Inflammation is involved in the progression of polycystic ovary syndrome." | 1.91 | Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue†. ( Ding, X; Li, G; Li, N; Lin, Y; Ma, Y; Wang, X; Xiong, C; Yang, Y; Yuan, Y; Zhang, Y; Zhang, Z, 2023) |
| "Clinical hyperandrogenism was positively correlated with FAI in younger women with PCOS." | 1.91 | Correlation between biochemical and clinical hyperandrogenism parameter in polycystic ovary syndrome in relation to age. ( Chen, S; Guo, Z; Hao, Y; Hu, P; Jin, F; Yu, Q, 2023) |
| " The former was combined with hyperinsulinemia and IR, while the latter was combined with glucolipid metabolic disorders, extremely heterogeneous hyperinsulinemia and IR." | 1.72 | Effects of dehydroepiandrosterone alone or in combination with a high-fat diet and antibiotic cocktail on the heterogeneous phenotypes of PCOS mouse models by regulating gut microbiota. ( Ding, X; Gu, L; Peng, Y; Wang, X; Xiong, C; Zhang, Y, 2022) |
| "Hyperandrogenism is the hallmark of polycystic ovary syndrome (PCOS)." | 1.48 | The use of dehydroepiandrosterone-treated rats is not a good animal model for the study of metabolic abnormalities in polycystic ovary syndrome. ( Ho, LT; Huang, SW; Juan, CC; Seow, KM; Ting, CH, 2018) |
| "Most patients with polycystic ovary syndrome have hyperandrogenism, caused by excess androgen synthesis." | 1.46 | The BMP4-Smad signaling pathway regulates hyperandrogenism development in a female mouse model. ( Ding, M; Dou, X; Du, SY; Liu, Y; Qian, SW; Tang, QQ; Wu, ZY; Xu, CJ; Zhang, FF; Zhang, W, 2017) |
| "Non-classic congenital adrenal hyperplasia (NC-CAH), one of the most common genetic disorders, is often associated with the clinical features of hyperandrogenism." | 1.40 | The effect of metformin on androgen production in diabetic women with non-classic congenital adrenal hyperplasia. ( Krysiak, R; Okopien, B, 2014) |
| "Hyperandrogenism is the primary manifestation of polycystic ovary syndrome (PCOS), which appears to be caused by excess exposure to androgen." | 1.40 | Long-term treatment with dehydroepiandrosterone may lead to follicular atresia through interaction with anti-Mullerian hormone. ( Baba, T; Endo, T; Honnma, H; Ikeda, K; Kiya, T; Morishita, M; Saito, T, 2014) |
| "Acne and hirsutism are common manifestations of hyperandrogenemia." | 1.36 | Ovarian morphology and prevalence of polycystic ovary syndrome in reproductive aged women with or without mild acne. ( Incki, K; Kelekci, KH; Kelekci, S; Ozdemir, O; Yilmaz, B, 2010) |
| "Treatment with metformin or rosiglitazone prevents excess adrenal androgen synthesis." | 1.34 | Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. ( Bahtiyar, G; Sacerdote, AS; Weiss, K, 2007) |
| "Dehydroepiandrosterone production was increased by atRA and 9-cis RA in normal cells and by atRA, 9-cis RA, and retinol in PCOS." | 1.33 | Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome. ( Hendricks, KL; Legro, RS; McAllister, JM; Nelson-DeGrave, VL; Strauss, JF; Wickenheisser, JK, 2005) |
| "When metformin was administered together with DHEA, the ovarian GSH content, NOS activity and PGE production did not differ when compared with controls." | 1.33 | The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice. ( Di Girolamo, G; Elia, E; Gonzalez, C; Luchetti, CG; Motta, AB; Sander, V; Solano, ME, 2006) |
| "Metformin treatment did not modify the percentage of CD4(+) and CD8(+) T cells from both axillar and retroperitoneal lymph nodes but prevented the increase of serum tumour necrosis factor +/- produced in DHEA-treated mice." | 1.33 | Metformin prevents embryonic resorption induced by hyperandrogenisation with dehydroepiandrosterone in mice. ( Di Girolamo, G; Elia, E; Gonzalez, C; Luchetti, CG; Motta, AB; Sander, V; Solano, ME, 2006) |
| "On the other hand, hyperandrogenism is associated with certain insulin-resistant conditions with hyperinsulinaemia, including the polycystic ovary syndrome (PCO)." | 1.31 | Two hyperandrogenic adolescent girls with congenital portosystemic shunt. ( Fujisawa, T; Hachiya, M; Hachiya, Y; Hoshino, K; Saji, T; Satoh, M; Yokoya, S, 2001) |
| "Hyperandrogenism was observed in women with upper-body obesity, as evident by significantly elevated free testosterone (P < ." | 1.30 | Hyperinsulinemia and sex hormones in healthy premenopausal women: relative contribution of obesity, obesity type, and duration of obesity. ( Ivandić, A; Jurić, M; Prpić-Krizevac, I; Sucić, M, 1998) |
| "However, PCO patients with NIDDM differed from those without diabetes in that they had elevated basal and corticotropin-stimulated adrenal steroids (cortisol, dehydroepiandrosterone [DHEA], dehydroepiandrosterone sulfate [DHEAS])." | 1.29 | Enhanced adrenocortical activity as a contributing factor to diabetes in hyperandrogenic women. ( Buffington, CK; Givens, JR; Kitabchi, AE, 1994) |
| "Flutamide was administered to seven hyperandrogenaemic women and five normal cycling women, at a dose of 250 mg on the evening of day 1, followed by daily doses of 750 mg for 6 days." | 1.29 | The effect of flutamide on pulsatile gonadotrophin secretion in hyperandrogenaemic women. ( Rabenbauer, B; Sir-Petermann, T; Wildt, L, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.09) | 18.7374 |
| 1990's | 17 (18.48) | 18.2507 |
| 2000's | 25 (27.17) | 29.6817 |
| 2010's | 36 (39.13) | 24.3611 |
| 2020's | 13 (14.13) | 2.80 |
| Authors | Studies |
|---|---|
| Mahmoud, AA | 1 |
| Elfiky, AM | 1 |
| Abo-Zeid, FS | 1 |
| Sriram, N | 1 |
| Madaan, P | 1 |
| Malhi, P | 1 |
| Sachdeva, N | 1 |
| Negi, S | 1 |
| Das, J | 1 |
| Kumar, R | 1 |
| Sahu, JK | 1 |
| Singhi, P | 1 |
| Carmina, E | 2 |
| Longo, RA | 1 |
| Wang, X | 2 |
| Gu, L | 1 |
| Zhang, Y | 2 |
| Xiong, C | 2 |
| Peng, Y | 1 |
| Ding, X | 2 |
| Jiang, Y | 1 |
| Yang, J | 1 |
| Du, K | 1 |
| Luo, K | 1 |
| Yuan, X | 1 |
| Hua, F | 1 |
| Forghani, N | 1 |
| Karimi, Z | 1 |
| Mokhtari, M | 1 |
| Shariati, M | 1 |
| Masjedi, F | 1 |
| Lin, Y | 1 |
| Li, G | 1 |
| Yuan, Y | 1 |
| Li, N | 1 |
| Yang, Y | 1 |
| Ma, Y | 1 |
| Zhang, Z | 1 |
| Guo, Z | 1 |
| Jin, F | 1 |
| Chen, S | 1 |
| Hu, P | 1 |
| Hao, Y | 1 |
| Yu, Q | 1 |
| Xiang, Y | 1 |
| Wang, H | 1 |
| Ding, H | 1 |
| Xu, T | 1 |
| Liu, X | 1 |
| Huang, Z | 1 |
| Wu, H | 1 |
| Ge, H | 1 |
| Zhai, J | 1 |
| Li, S | 1 |
| Hu, M | 1 |
| Di, F | 1 |
| Liu, J | 1 |
| Du, Y | 1 |
| Ahmed, AA | 1 |
| Moselhy, SS | 1 |
| Kumosani, TA | 1 |
| Huwait, EA | 1 |
| Al-Ghamdi, MA | 1 |
| Al-Madani, KA | 1 |
| AlToukhi, MH | 1 |
| Kumosani, AT | 1 |
| Chen, F | 1 |
| Chen, M | 1 |
| Zhang, W | 2 |
| Yin, H | 1 |
| Chen, G | 1 |
| Huang, Q | 1 |
| Yang, X | 1 |
| Chen, L | 1 |
| Lin, C | 1 |
| Yin, G | 1 |
| de Medeiros, SF | 1 |
| Barbosa, BB | 1 |
| de Medeiros, AKLWY | 1 |
| de Medeiros, MAS | 1 |
| Yamamoto, MMW | 1 |
| Liu, Y | 2 |
| Du, SY | 1 |
| Ding, M | 1 |
| Dou, X | 1 |
| Zhang, FF | 1 |
| Wu, ZY | 1 |
| Qian, SW | 1 |
| Tang, QQ | 1 |
| Xu, CJ | 1 |
| Al Nofal, A | 1 |
| Viers, LD | 1 |
| Javed, A | 1 |
| Ara, J | 1 |
| Nuwormegbe, SA | 1 |
| Sajo, MEJ | 1 |
| Kim, SK | 1 |
| Shim, KY | 1 |
| Lee, KJ | 1 |
| Yang, YL | 1 |
| Sun, LF | 1 |
| Yu, Y | 1 |
| Xiao, TX | 1 |
| Wang, BB | 1 |
| Ren, PG | 1 |
| Tang, HR | 1 |
| Zhang, JV | 1 |
| Bracho, GS | 1 |
| Altamirano, GA | 1 |
| Kass, L | 1 |
| Luque, EH | 1 |
| Bosquiazzo, VL | 1 |
| Seow, KM | 1 |
| Ting, CH | 1 |
| Huang, SW | 1 |
| Ho, LT | 1 |
| Juan, CC | 1 |
| Velez, LM | 2 |
| Abruzzese, GA | 2 |
| Heber, MF | 2 |
| Ferreira, SR | 2 |
| Motta, AB | 9 |
| da Cunha, MG | 1 |
| Fonseca, FL | 1 |
| Machado, CD | 1 |
| Mazza, A | 1 |
| Fruci, B | 1 |
| Guzzi, P | 1 |
| D'Orrico, B | 1 |
| Malaguarnera, R | 1 |
| Veltri, P | 1 |
| Fava, A | 1 |
| Belfiore, A | 1 |
| Louwers, YV | 1 |
| de Jong, FH | 1 |
| van Herwaarden, NA | 1 |
| Stolk, L | 1 |
| Fauser, BC | 1 |
| Uitterlinden, AG | 2 |
| Laven, JS | 1 |
| Medeiros, SF | 2 |
| Gil-Junior, AB | 1 |
| Barbosa, JS | 2 |
| Isaías, ED | 1 |
| Yamamoto, MM | 2 |
| Wang, YX | 1 |
| Zhu, WJ | 1 |
| Xie, BG | 1 |
| González, F | 4 |
| Sia, CL | 1 |
| Bearson, DM | 2 |
| Blair, HE | 3 |
| Ikeda, K | 1 |
| Baba, T | 1 |
| Morishita, M | 1 |
| Honnma, H | 1 |
| Endo, T | 1 |
| Kiya, T | 1 |
| Saito, T | 1 |
| Goodarzi, MO | 1 |
| Azziz, R | 3 |
| Krysiak, R | 1 |
| Okopien, B | 1 |
| Sreekumaran Nair, K | 1 |
| Basal, E | 3 |
| Schimke, JM | 3 |
| Oostdijk, W | 1 |
| Idkowiak, J | 1 |
| Mueller, JW | 1 |
| House, PJ | 1 |
| Taylor, AE | 2 |
| O'Reilly, MW | 2 |
| Hughes, BA | 1 |
| de Vries, MC | 1 |
| Kant, SG | 1 |
| Santen, GW | 1 |
| Verkerk, AJ | 1 |
| Wit, JM | 1 |
| Losekoot, M | 1 |
| Arlt, W | 2 |
| Chernykh, ER | 1 |
| Leplina, OY | 1 |
| Tikhonova, MA | 1 |
| Seledtsova, NV | 1 |
| Tyrinova, TV | 1 |
| Khonina, NA | 1 |
| Ostanin, AA | 1 |
| Pasman, NM | 1 |
| Reynoso, RM | 1 |
| Wang, F | 1 |
| Pan, J | 1 |
| Meng, Q | 1 |
| Lv, P | 1 |
| Qu, F | 1 |
| Ding, GL | 1 |
| Klausen, C | 1 |
| Leung, PC | 1 |
| Chan, HC | 1 |
| Yao, W | 1 |
| Zhou, CY | 1 |
| Shi, B | 1 |
| Zhang, J | 1 |
| Sheng, J | 1 |
| Huang, H | 1 |
| Tessaro, I | 1 |
| Modina, SC | 1 |
| Franciosi, F | 1 |
| Sivelli, G | 1 |
| Terzaghi, L | 1 |
| Lodde, V | 1 |
| Luciano, AM | 1 |
| Kempegowda, P | 1 |
| Jenkinson, C | 1 |
| Quanson, JL | 1 |
| Storbeck, KH | 1 |
| Diamanti-Kandarakis, E | 1 |
| Dattilo, M | 1 |
| Macut, D | 1 |
| Duntas, L | 1 |
| Gonos, ES | 1 |
| Goulis, DG | 1 |
| Gantenbein, CK | 1 |
| Kapetanou, M | 1 |
| Koukkou, E | 1 |
| Lambrinoudaki, I | 1 |
| Michalaki, M | 1 |
| Eftekhari-Nader, S | 1 |
| Pasquali, R | 2 |
| Peppa, M | 1 |
| Tzanela, M | 1 |
| Vassilatou, E | 1 |
| Vryonidou, A | 1 |
| Harper, JC | 1 |
| Elia, E | 3 |
| Vighi, S | 1 |
| Lombardi, E | 1 |
| Chen, Y | 1 |
| Qiao, J | 1 |
| Yan, LY | 1 |
| Huang, S | 1 |
| Zhao, PL | 1 |
| Yan, J | 1 |
| Sander, VA | 1 |
| Facorro, GB | 1 |
| Piehl, L | 1 |
| Rubín de Celis, E | 1 |
| Gambineri, A | 1 |
| Forlani, G | 1 |
| Munarini, A | 1 |
| Tomassoni, F | 1 |
| Cognigni, GE | 1 |
| Ciampaglia, W | 1 |
| Pagotto, U | 1 |
| Walker, BR | 1 |
| Dumont, T | 1 |
| Black, AY | 1 |
| Ahmet, A | 1 |
| Fleming, NA | 1 |
| Shayya, R | 1 |
| Chang, RJ | 2 |
| Kelekci, KH | 1 |
| Kelekci, S | 1 |
| Incki, K | 1 |
| Ozdemir, O | 1 |
| Yilmaz, B | 1 |
| Faut, M | 1 |
| Elia, EM | 2 |
| Parborell, F | 1 |
| Cugnata, NM | 1 |
| Tesone, M | 1 |
| Tena, G | 1 |
| Moran, C | 3 |
| Romero, R | 1 |
| Moran, S | 1 |
| Rosencrantz, MA | 1 |
| Coffler, MS | 1 |
| Haggan, A | 1 |
| Duke, KB | 1 |
| Donohue, MC | 1 |
| Shayya, RF | 1 |
| Su, HI | 1 |
| Philibert, P | 1 |
| Biason-Lauber, A | 1 |
| Gueorguieva, I | 1 |
| Stuckens, C | 1 |
| Pienkowski, C | 1 |
| Lebon-Labich, B | 1 |
| Paris, F | 1 |
| Sultan, C | 1 |
| Pustovrh, C | 1 |
| Amalfi, S | 1 |
| Devoto, L | 1 |
| Sathyapalan, T | 1 |
| Smith, KA | 1 |
| Coady, AM | 1 |
| Kilpatrick, ES | 1 |
| Atkin, SL | 1 |
| Nair, KS | 2 |
| Daniels, JK | 2 |
| Thiboutot, D | 1 |
| Chen, W | 1 |
| Wu, FC | 1 |
| von Eckardstein, A | 1 |
| BORGHI, A | 1 |
| Reyna, R | 2 |
| Boots, LS | 1 |
| El-Khayat, HA | 1 |
| Abd El-Basset, FZ | 1 |
| Tomoum, HY | 1 |
| Tohamy, SM | 1 |
| Zaky, AA | 1 |
| Mohamed, MS | 1 |
| Hakky, SM | 1 |
| El Barbary, NS | 1 |
| Nassef, NM | 1 |
| Wickenheisser, JK | 1 |
| Nelson-DeGrave, VL | 1 |
| Hendricks, KL | 1 |
| Legro, RS | 1 |
| Strauss, JF | 1 |
| McAllister, JM | 1 |
| Zhou, R | 1 |
| Bird, IM | 1 |
| Dumesic, DA | 1 |
| Abbott, DH | 1 |
| Marouliss, GB | 1 |
| Triantafillidis, IK | 1 |
| Stanczyk, FZ | 1 |
| Sander, V | 2 |
| Luchetti, CG | 2 |
| Solano, ME | 2 |
| Di Girolamo, G | 2 |
| Gonzalez, C | 2 |
| Mueller, A | 1 |
| Cupisti, S | 1 |
| Binder, H | 1 |
| Hoffmann, I | 1 |
| Kiesewetter, F | 1 |
| Beckmann, MW | 1 |
| Dittrich, R | 1 |
| Willenberg, HS | 1 |
| Bahlo, M | 1 |
| Schott, M | 1 |
| Wertenbruch, T | 1 |
| Feldkamp, J | 1 |
| Scherbaum, WA | 1 |
| Bahtiyar, G | 1 |
| Weiss, K | 1 |
| Sacerdote, AS | 1 |
| Fanta, M | 1 |
| Cibula, D | 2 |
| Vrbíková, J | 1 |
| Devoto, E | 1 |
| Aravena, L | 1 |
| Gaete, X | 1 |
| Morris, RS | 1 |
| Wong, IL | 1 |
| Hatch, IE | 1 |
| Gentschein, E | 1 |
| Paulson, RJ | 1 |
| Lobo, RA | 1 |
| Sütterlin, M | 1 |
| Steck, T | 1 |
| Paula, FJ | 1 |
| Dick-de-Paula, I | 1 |
| Pontes, A | 1 |
| Schmitt, FC | 1 |
| Mendonça, BB | 1 |
| Foss, MC | 1 |
| Buffington, CK | 1 |
| Givens, JR | 1 |
| Kitabchi, AE | 1 |
| Sir-Petermann, T | 1 |
| Rabenbauer, B | 1 |
| Wildt, L | 1 |
| Graf, MA | 1 |
| Pelzer, V | 1 |
| Umlauf, A | 1 |
| Kühn-Velten, WN | 1 |
| Dewailly, D | 1 |
| Gustafson, O | 1 |
| Nylund, L | 1 |
| Carlström, K | 1 |
| Isojärvi, JI | 1 |
| Laatikainen, TJ | 1 |
| Knip, M | 1 |
| Pakarinen, AJ | 1 |
| Juntunen, KT | 1 |
| Myllylä, VV | 1 |
| Moghetti, P | 1 |
| Castello, R | 1 |
| Negri, C | 1 |
| Tosi, F | 1 |
| Spiazzi, GG | 1 |
| Brun, E | 1 |
| Balducci, R | 1 |
| Toscano, V | 1 |
| Muggeo, M | 1 |
| Valentino, R | 1 |
| Tommaselli, AP | 1 |
| Savastano, S | 1 |
| Dorato, M | 1 |
| Rossi, R | 1 |
| Lombardi, G | 1 |
| Anderson, E | 1 |
| Lee, GY | 1 |
| O'Brien, K | 1 |
| Ivandić, A | 1 |
| Prpić-Krizevac, I | 1 |
| Sucić, M | 1 |
| Jurić, M | 1 |
| Sir, T | 1 |
| López, G | 1 |
| Castillo, T | 1 |
| Muñoz, S | 1 |
| Durruty, P | 1 |
| Calvillán, M | 1 |
| Potter, HD | 1 |
| Boots, LR | 1 |
| Ibáñez, L | 1 |
| Potau, N | 1 |
| Marcos, MV | 1 |
| de Zegher, F | 1 |
| Meloun, M | 1 |
| Hill, M | 1 |
| Satoh, M | 1 |
| Yokoya, S | 1 |
| Hachiya, Y | 1 |
| Hachiya, M | 1 |
| Fujisawa, T | 1 |
| Hoshino, K | 1 |
| Saji, T | 1 |
| Szathmári, M | 1 |
| Vásárhelyi, B | 1 |
| Tulassay, T | 1 |
| Saenger, P | 1 |
| Dimartino-Nardi, J | 1 |
| Mathew, RP | 1 |
| Najjar, JL | 1 |
| Lorenz, RA | 1 |
| Mayes, DE | 1 |
| Russell, WE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phenotypic Components of Polycystic Ovary Syndrome Determine Endometrial Vitamin D Receptor mRNA Expression Pattern[NCT05885633] | 64 participants (Actual) | Interventional | 2022-10-21 | Completed | |||
| Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study[NCT01526616] | 56 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| Phase III Study of Efficacy of High Dose Erythropoietin to Prevent Hypoxic-ischemic Encephalopathy Sequelae in Term Newborn[NCT01732146] | Phase 3 | 120 participants (Actual) | Interventional | 2013-03-28 | Completed | ||
| Antioxidants vs.Ovarian Bio-stimulation Therapy to Rescue the Ovarian Reserve[NCT03621683] | 78 participants (Actual) | Interventional | 2016-01-06 | Completed | |||
| Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)[NCT02145247] | 39 participants (Actual) | Interventional | 2014-05-31 | Completed | |||
| Theca Cell Function in Women With Polycystic Ovary Syndrome[NCT00747617] | Phase 3 | 25 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men Title Changed With New Protocol (12/14/09): Hormonal Regulation of HDL-C in Men[NCT00729859] | Phase 2 | 31 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| The Effect of Dihydrotestosterone (DHT) on Prostate Tissue Androgen Concentrations and Inflammation in Normal Men[NCT00490022] | Phase 1/Phase 2 | 31 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~Blood samples will be obtained before and after r-hCG adminstration" (NCT02145247)
Timeframe: before and 24 hours after adminisration of r-hCG
| Intervention | percent change (Mean) |
|---|---|
| Normal Adult Women | 67 |
| Women With PCOS | 140 |
Mean serum testosterone levels before and after hCG injection. Serum testosterone levels before (-0.5 and 0 hrs) were averaged to achieve a single value (NCT00747617)
Timeframe: -0.5, 0, 24 hrs
| Intervention | ng/ml (Mean) |
|---|---|
| PCOS | 0.6 |
| Normal | 0.3 |
Assess serum 17OHP levels following each dose of hCG adminstration in PCOS and normal subjects (NCT00747617)
Timeframe: 24 hrs post dose
| Intervention | ng/ml (Mean) | ||||
|---|---|---|---|---|---|
| 17OHP post 10 micrograms | 17OHP level post 1 micrograms | 17OHP level post 25 micrograms | 17OHP level post 100 micrograms | 17OHP level post 250 micrograms | |
| Normal | 1.2 | 1.0 | 1.7 | 2.2 | 2.1 |
| PCOS | 2.0 | 1.1 | 2.7 | 3.3 | 4.0 |
Number of CD33 + CD134+ cells as a percentage of all lymphocytes (NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | percentage of all lymphocytes (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel + Placebo Pill | 0.101 | 0.081 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | pmol/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 95.4 | 31.9 |
| Group 2: Acyline, Testosterone Gel | 117.8 | 109.0 |
| Group 3: Acyline, Testosterone Gel, Anastrozole Pill | 96.3 | 36.5 |
(NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | mmol/L (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total cholesterol Day 0 | Total cholesterol Day 28 | Total cholesterol Day 56 | LDL choesterol Day 0 | LDL cholesterol Day 28 | LDL cholesterol Day 56 | HDL cholesterol Day 0 | HDL cholesterol Day 28 | HDL cholesterol Day 56 | Triglycerides Day 0 | Triglycerides Day 28 | Triglycerides Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 4.97 | 5.44 | 4.95 | 2.95 | 3.29 | 2.87 | 1.19 | 1.37 | 1.19 | 1.79 | 1.73 | 1.89 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 4.48 | 4.51 | 4.14 | 2.77 | 2.80 | 2.49 | 1.32 | 1.32 | 1.32 | 0.82 | 0.86 | 0.80 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 4.56 | 4.56 | 4.27 | 2.67 | 2.75 | 2.51 | 1.40 | 1.32 | 1.30 | 1.08 | 1.08 | 1.02 |
(NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | picomolar (Mean) | ||
|---|---|---|---|
| Baseline | Day 28 | Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 54 | 69 | 54 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 65 | 59 | 64 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 50 | 42 | 50 |
(NCT00729859)
Timeframe: Baseline, 28 days
| Intervention | IU/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 4.2 | 0.42 |
| Group 2: Acyline, Testosterone Gel | 2.9 | 0.39 |
| Group 3: Acyline, Testosterone Gel, Anastrazole Pill | 2.5 | 0.87 |
HOMA IR is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher HOMA IR numbers are associated with increased insulin resistance and decreased insulin sensitivity. (NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | HOMA score (Mean) | ||
|---|---|---|---|
| Baseline | Day 28 | Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 1.8 | 2.4 | 2.2 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 2.0 | 1.9 | 1.9 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 1.6 | 1.4 | 1.7 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | IU/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 4.3 | 0.31 |
| Group 2: Acyline, Testosterone Gel | 4.7 | 0.69 |
| Group 3: Acyline, Testosterone Gel, Anastrozole | 4.4 | 1.55 |
QUICKI is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher QUICKI are associated with decreased insulin resistance and increased insulin sensitivity. (NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | QUICKI index (Mean) | ||
|---|---|---|---|
| Baseline | Day 28 | Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 0.36 | 0.34 | 0.35 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 0.35 | 0.35 | 0.35 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 0.36 | 0.38 | 0.36 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | nmol/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 34.9 | 37.5 |
| Group 2: Acyline, Testosterone Gel | 23.0 | 22.1 |
| Group 3: Acyline, Testosterone Gel, Anastrozole Pill | 27.6 | 25.1 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | nmol/L (Mean) | |
|---|---|---|
| Baseline testosterone concentration | Day 28 testosterone concentration | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 15.4 | 0.8 |
| Group 2: Acyline, Testosterone Gel | 16.3 | 17.8 |
| Group 3: Acyline, Testosterone Gel, Anastrozole | 16.5 | 19.0 |
Prostate epithelial cell proliferation in the prostate biopsy tissue was measured using Ki-67 immunohistochemical staining of prostate epithelium as a marker of cell proliferation (values are number of Ki-67 positive stained cells per 100 prostate epithelial cells). The placebo and treatment groups were compared. (NCT00490022)
Timeframe: 28-days
| Intervention | #pos.Ki-67cells per100 prst. epth cells (Mean) |
|---|---|
| Placebo DHT Gel | 1.3 |
| DHT Gel | 0.7 |
After 4 weeks of either daily dihydrotestosterone transdermal gel or placebo gel, subjects underwent a prostate biopsy. Intraprostatic hormone concentrations, specifically DHT and Testosterone, were measured. Unit of measure is ng/g. (NCT00490022)
Timeframe: 28-days
| Intervention | ng/g (Mean) | |
|---|---|---|
| DHT concentrations | Testosterone Concentrations | |
| DHT Gel | 3.1 | 0.4 |
| Placebo DHT Gel | 2.8 | 0.6 |
9 reviews available for dehydroepiandrosterone and Hyperandrogenism
| Article | Year |
|---|---|
DHEA, DHEAS and PCOS.
Topics: Androgens; Animals; Body Mass Index; Cardiovascular Diseases; Dehydroepiandrosterone; Dehydroepiandr | 2015 |
MECHANISMS IN ENDOCRINOLOGY: Aging and anti-aging: a Combo-Endocrinology overview.
Topics: Adjuvants, Immunologic; Aging; Androgens; Antioxidants; Circadian Rhythm; Dehydroepiandrosterone; Di | 2017 |
Reproductive endocrinology of adolescent polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Anovulation; Anti-Mullerian Hormone; Child; Dehydroepiandrosterone; Fe | 2010 |
Dehydroepiandrosterone to induce murine models for the study of polycystic ovary syndrome.
Topics: Androgens; Animals; Dehydroepiandrosterone; Disease Models, Animal; Embryo Loss; Female; Humans; Hyp | 2010 |
Update and future of hormonal therapy in acne.
Topics: Acne Vulgaris; Androgen Antagonists; Androgens; Contraceptives, Oral, Hormonal; Dehydroepiandrostero | 2003 |
Androgens and coronary artery disease.
Topics: Adult; Animals; Cardiovascular Physiological Phenomena; Cardiovascular System; Cholesterol, HDL; Cor | 2003 |
Androgens and coronary artery disease.
Topics: Adult; Animals; Cardiovascular Physiological Phenomena; Cardiovascular System; Cholesterol, HDL; Cor | 2003 |
Androgens and coronary artery disease.
Topics: Adult; Animals; Cardiovascular Physiological Phenomena; Cardiovascular System; Cholesterol, HDL; Cor | 2003 |
Androgens and coronary artery disease.
Topics: Adult; Animals; Cardiovascular Physiological Phenomena; Cardiovascular System; Cholesterol, HDL; Cor | 2003 |
Polycystic ovarian disease: the adrenal connection.
Topics: Adrenal Glands; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dexamethaso | 2006 |
Diagnosis of hyperandrogenism: biochemical criteria.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Acne Vulgaris; Alopecia; Ammonium Sulfate; Androgens; Androst | 2006 |
Premature adrenarche.
Topics: Adrenal Glands; Androgens; Blood Glucose; Child; Dehydroepiandrosterone; Female; Humans; Hyperandrog | 2001 |
12 trials available for dehydroepiandrosterone and Hyperandrogenism
| Article | Year |
|---|---|
In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Female; Hirsutism; | 2014 |
Hyperandrogenism induces a proinflammatory TNFα response to glucose ingestion in a receptor-dependent fashion.
Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Double-Blind Method; | 2014 |
Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome.
Topics: Adolescent; Adrenocortical Hyperfunction; Adult; Androstenedione; Basal Metabolism; Cosyntropin; Deh | 2009 |
Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Chorionic Gonadotropin; Dehydroepiandrosterone; Dose-Response Re | 2011 |
Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Chorionic Gonadotropin; Dehydroepiandrosterone; Dose-Response Re | 2011 |
Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Chorionic Gonadotropin; Dehydroepiandrosterone; Dose-Response Re | 2011 |
Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Chorionic Gonadotropin; Dehydroepiandrosterone; Dose-Response Re | 2011 |
Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study.
Topics: Adrenal Glands; Adult; Androstenedione; Atorvastatin; Dehydroepiandrosterone; Dehydroepiandrosterone | 2012 |
Hyperandrogenism sensitizes mononuclear cells to promote glucose-induced inflammation in lean reproductive-age women.
Topics: Adult; Body Mass Index; Cell Nucleus; Cytokines; Dehydroepiandrosterone; Double-Blind Method; Female | 2012 |
Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women.
Topics: Adult; Blood Glucose; Body Composition; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Doub | 2012 |
Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess.
Topics: 17-alpha-Hydroxyprogesterone; 3-Hydroxysteroid Dehydrogenases; Adrenal Cortex; Adrenocorticotropic H | 2004 |
[Prolonged remission of female hyperandrogenism after discontinuing glucocorticoid therapy].
Topics: Adolescent; Adult; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dexamethasone; Female; Fo | 1995 |
Prorenin is elevated in polycystic ovary syndrome and may reflect hyperandrogenism.
Topics: Adolescent; Adult; Androstenedione; Angiotensin II; Clomiphene; Dehydroepiandrosterone; Dehydroepian | 1995 |
Sensitivity of plasma insulin levels in obese and non-obese women with functional hyperandrogenism.
Topics: Adult; Androstenedione; Body Mass Index; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Fem | 1995 |
Corticotropin-releasing hormone: a potent androgen secretagogue in girls with hyperandrogenism after precocious pubarche.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Androgens; Body Mass Index; Corticotropin-Releasing | 1999 |
71 other studies available for dehydroepiandrosterone and Hyperandrogenism
| Article | Year |
|---|---|
The anti-androgenic effect of quercetin on hyperandrogenism and ovarian dysfunction induced in a dehydroepiandrosterone rat model of polycystic ovary syndrome.
Topics: Androgen Antagonists; Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Hyperandrogen | 2022 |
Evaluation of Hyperandrogenism in Children with Autism Spectrum Disorder.
Topics: Androgens; Androstenedione; Autism Spectrum Disorder; Child; Dehydroepiandrosterone; Humans; Hyperan | 2022 |
Increased Prevalence of Elevated DHEAS in PCOS Women with Non-Classic (B or C) Phenotypes: A Retrospective Analysis in Patients Aged 20 to 29 Years.
Topics: Androgens; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Humans; | 2022 |
Effects of dehydroepiandrosterone alone or in combination with a high-fat diet and antibiotic cocktail on the heterogeneous phenotypes of PCOS mouse models by regulating gut microbiota.
Topics: Animals; Dehydroepiandrosterone; Diet, High-Fat; Female; Gastrointestinal Microbiome; Humans; Hypera | 2022 |
1,25-Dihydroxyvitamin D3 alleviates hyperandrogen-induced ferroptosis in KGN cells.
Topics: Calcitriol; Dehydroepiandrosterone; Female; Ferroptosis; Humans; Hyperandrogenism; Polycystic Ovary | 2023 |
Association of Oxidative Stress with Kidney Injury in a Hyperandrogenemic Female Rat Model.
Topics: Animals; Antioxidants; Dehydroepiandrosterone; Female; Humans; Hyperandrogenism; Kidney; Kidney Dise | 2023 |
Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue†.
Topics: Adipose Tissue, White; Animals; Dehydroepiandrosterone; Female; Glucagon-Like Peptide-1 Receptor; Hu | 2023 |
Correlation between biochemical and clinical hyperandrogenism parameter in polycystic ovary syndrome in relation to age.
Topics: Acne Vulgaris; Aged; Androgens; Dehydroepiandrosterone; Female; Humans; Hyperandrogenism; Polycystic | 2023 |
Hyperandrogenism drives ovarian inflammation and pyroptosis: A possible pathogenesis of PCOS follicular dysplasia.
Topics: Animals; Dehydroepiandrosterone; Female; Humans; Hyperandrogenism; Inflammation; Mice; Polycystic Ov | 2023 |
Decreased brain and muscle ARNT-like protein 1 expression mediated the contribution of hyperandrogenism to insulin resistance in polycystic ovary syndrome.
Topics: 3T3-L1 Cells; Adipocytes; Animals; ARNTL Transcription Factors; Brain; Circadian Clocks; Dehydroepia | 2020 |
Ultrasonographic and biochemical assessments as early prediction of polycystic ovarian syndrome in obese women.
Topics: Adult; Anovulation; Body Mass Index; Case-Control Studies; Dehydroepiandrosterone; Female; Follicle | 2020 |
Comparison of the efficacy of different androgens measured by LC-MS/MS in representing hyperandrogenemia and an evaluation of adrenal-origin androgens with a dexamethasone suppression test in patients with PCOS.
Topics: Adrenal Cortex Function Tests; Adult; Androstenedione; Area Under Curve; Case-Control Studies; Chrom | 2021 |
Differential Effects of Various Androgens on Polycystic Ovary Syndrome.
Topics: Adult; Androgens; Body Mass Index; Cross-Sectional Studies; Dehydroepiandrosterone; Dehydroepiandros | 2021 |
The BMP4-Smad signaling pathway regulates hyperandrogenism development in a female mouse model.
Topics: Androgens; Animals; Bone Morphogenetic Protein 4; Cells, Cultured; Dehydroepiandrosterone; Disease M | 2017 |
Can the source of hyperandrogenism in adolescents with polycystic ovary syndrome predict metabolic phenotype?
Topics: Adolescent; Adrenal Glands; Cohort Studies; Dehydroepiandrosterone; Female; Humans; Hyperandrogenism | 2017 |
Potential therapeutic effect of alkaline reduced water in polycystic ovarian syndrome.
Topics: Animals; Dehydroepiandrosterone; Female; Humans; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydr | 2017 |
Deficiency of Gpr1 improves steroid hormone abnormality in hyperandrogenized mice.
Topics: Animals; Cells, Cultured; Dehydroepiandrosterone; Disease Models, Animal; Estradiol; Female; Hyperan | 2018 |
Hyperandrogenism Induces Histo-Architectural Changes in the Rat Uterus.
Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Estrogen Receptor alpha; Female; Hyperandro | 2019 |
The use of dehydroepiandrosterone-treated rats is not a good animal model for the study of metabolic abnormalities in polycystic ovary syndrome.
Topics: Adiposity; Animals; Blood Glucose; Dehydroepiandrosterone; Disease Models, Animal; Estrous Cycle; Fa | 2018 |
Treatment with the synthetic PPARG ligand pioglitazone ameliorates early ovarian alterations induced by dehydroepiandrosterone in prepubertal rats.
Topics: Animals; Co-Repressor Proteins; Dehydroepiandrosterone; Disease Models, Animal; Estradiol; Female; H | 2019 |
Androgenic hormone profile of adult women with acne.
Topics: Acne Vulgaris; Adolescent; Adult; Androgens; Androstenedione; Dehydroepiandrosterone; Female; Humans | 2013 |
Variants in SULT2A1 affect the DHEA sulphate to DHEA ratio in patients with polycystic ovary syndrome but not the hyperandrogenic phenotype.
Topics: Adult; Alleles; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Genetic Predispositi | 2013 |
New insights into steroidogenesis in normo- and hyperandrogenic polycystic ovary syndrome patients.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Glands; Adrenal Hyperplasia, Congenital; Adult; Case-Control S | 2013 |
Expression of PPAR-γ in adipose tissue of rats with polycystic ovary syndrome induced by DHEA.
Topics: Adipose Tissue; Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Gene Expression Reg | 2014 |
Long-term treatment with dehydroepiandrosterone may lead to follicular atresia through interaction with anti-Mullerian hormone.
Topics: Animals; Anti-Mullerian Hormone; Dehydroepiandrosterone; Female; Follicular Atresia; Hyperandrogenis | 2014 |
The effect of metformin on androgen production in diabetic women with non-classic congenital adrenal hyperplasia.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Hyperplasia, Congenital; Adult; Androgens; Blood Glucose; Dehy | 2014 |
Induction of hyperandrogenism in lean reproductive-age women stimulates proatherogenic inflammation.
Topics: Adult; Androgens; C-Reactive Protein; Dehydroepiandrosterone; Female; Humans; Hyperandrogenism; Infl | 2015 |
Comparison of steroidogenic pathways among normoandrogenic and hyperandrogenic polycystic ovary syndrome patients and normal cycling women.
Topics: Adult; Androgens; Androstenedione; Case-Control Studies; Dehydroepiandrosterone; Estradiol; Female; | 2015 |
PAPSS2 deficiency causes androgen excess via impaired DHEA sulfation--in vitro and in vivo studies in a family harboring two novel PAPSS2 mutations.
Topics: Adolescent; Adult; Androgens; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Family; Female | 2015 |
Elevated levels of dehydroepiandrosterone as a potential mechanism of dendritic cell impairment during pregnancy.
Topics: Abortion, Spontaneous; Adult; Cell Differentiation; Cells, Cultured; Dehydroepiandrosterone; Dendrit | 2015 |
Effect of hyperandrogenism on ovarian function.
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; Animals; Aromatase; Chorionic Gon | 2015 |
Alternative splicing of the androgen receptor in polycystic ovary syndrome.
Topics: Adult; Alternative Splicing; Base Sequence; Cells, Cultured; Dehydroepiandrosterone; Female; Gene Ex | 2015 |
Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome.
Topics: Adjuvants, Immunologic; Administration, Oral; Analysis of Variance; Animals; Aromatase; Dehydroepian | 2015 |
11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome.
Topics: Adult; Androgens; Androstenedione; Androstenes; Blood Glucose; Case-Control Studies; Chromatography, | 2017 |
Evaluating hyperandrogenism: a challenge in acne management.
Topics: 17-alpha-Hydroxyprogesterone; Acne Vulgaris; Androgens; Dehydroepiandrosterone; Diagnosis, Different | 2008 |
Detrimental effects of hyperandrogenism on uterine functions.
Topics: Adjuvants, Immunologic; Animals; Catalase; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; C | 2008 |
Selective impairment in glycogen synthase kinase-3 and mitogen-activated protein kinase phosphorylation: comparisons with the hyperandrogenic and the hyperinsulinemic rats.
Topics: Animals; Blood Glucose; Chorionic Gonadotropin; Dehydroepiandrosterone; Estrous Cycle; Extracellular | 2009 |
Effect of DHEA and metformin on corpus luteum in mice.
Topics: Animals; Corpus Luteum; Dehydroepiandrosterone; Dinoprost; Female; Hyperandrogenism; Hypoglycemic Ag | 2009 |
Isolated transient neonatal clitoromegaly with hyperandrogenism of unknown etiology.
Topics: Clitoris; Dehydroepiandrosterone; Female; Humans; Hyperandrogenism; Hyperplasia; Infant, Newborn; In | 2009 |
Ovarian morphology and prevalence of polycystic ovary syndrome in reproductive aged women with or without mild acne.
Topics: 17-alpha-Hydroxyprogesterone; Acne Vulgaris; Adolescent; Adult; Age of Onset; Cross-Sectional Studie | 2010 |
Peroxisome proliferator-activated receptor gamma and early folliculogenesis during an acute hyperandrogenism condition.
Topics: Acute Disease; Animals; Apoptosis; Chorionic Gonadotropin; Dehydroepiandrosterone; Female; Gene Expr | 2011 |
Ovarian morphology and endocrine function in polycystic ovary syndrome.
Topics: Adult; Anthropometry; Body Mass Index; Case-Control Studies; Cross-Sectional Studies; Dehydroepiandr | 2011 |
Molecular analysis of WNT4 gene in four adolescent girls with mullerian duct abnormality and hyperandrogenism (atypical Mayer-Rokitansky-Küster-Hauser syndrome).
Topics: 17-alpha-Hydroxyprogesterone; 46, XX Disorders of Sex Development; Abnormalities, Multiple; Adolesce | 2011 |
Link between metformin and the peroxisome proliferator-activated receptor γ pathway in the uterine tissue of hyperandrogenized prepubertal mice.
Topics: Animals; Arachidonate 12-Lipoxygenase; Arachidonate 15-Lipoxygenase; Dehydroepiandrosterone; Disease | 2011 |
[AN ALTERATION IN HORMONAL BIOSYNTHESIS IN THE OVARY, A POSSIBLE CAUSE OF HYPERANDROGENISM IN THE STEIN-LEVENTHAL SYNDROME].
Topics: Androgens; Dehydroepiandrosterone; Estrogens; Female; Humans; Hydroxyprogesterones; Hyperandrogenism | 1963 |
Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Dehydroepiandrosterone; Epilepsy; Female; Growth; | 2004 |
Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome.
Topics: Alitretinoin; Antineoplastic Agents; Cholesterol Side-Chain Cleavage Enzyme; Dehydroepiandrosterone; | 2005 |
Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Androgens; Animals; Area Under Curve; Dehydroepiandrost | 2005 |
The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice.
Topics: Adjuvants, Immunologic; Administration, Oral; AMP-Activated Protein Kinases; Animals; Catalase; Cycl | 2006 |
Metformin prevents embryonic resorption induced by hyperandrogenisation with dehydroepiandrosterone in mice.
Topics: Animals; Blood Glucose; CD4-CD8 Ratio; Dehydroepiandrosterone; Estradiol; Female; Fetal Resorption; | 2006 |
Endocrinological markers for assessment of hyperandrogenemia in hirsute women.
Topics: Adult; Androgens; Biomarkers; Dehydroepiandrosterone; Dihydrotestosterone; Female; Hirsutism; Humans | 2007 |
Helpful diagnostic markers of steroidogenesis for defining hyperandrogenemia in hirsute women.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Aged; Androstenedione; Biomarkers; Cortodoxone; Deh | 2008 |
Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenal Glands; Adult; Aged; Antipsychotic Agents; Cortodo | 2007 |
Prevalence of nonclassic adrenal hyperplasia (NCAH) in hyperandrogenic women.
Topics: 17-alpha-Hydroxyprogesterone; Acne Vulgaris; Adrenal Hyperplasia, Congenital; Adrenocorticotropic Ho | 2008 |
Hyperandrogenism due to 3 beta-hydroxysteroid dehydrogenase deficiency with accessory adrenocortical tissue: a hormonal and metabolic evaluation.
Topics: 3-Hydroxysteroid Dehydrogenases; Adrenal Rest Tumor; Adrenocorticotropic Hormone; Adult; Androstened | 1994 |
Enhanced adrenocortical activity as a contributing factor to diabetes in hyperandrogenic women.
Topics: Adrenal Cortex; Adult; Dehydroepiandrosterone; Diabetes Mellitus, Type 2; Female; Glucose Tolerance | 1994 |
The effect of flutamide on pulsatile gonadotrophin secretion in hyperandrogenaemic women.
Topics: Adolescent; Adult; Androgens; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfat | 1993 |
Partial uncoupling of luteinizing hormone and prolactin pulse coincidence in hyperandrogenemic women.
Topics: Adolescent; Adult; Androstenedione; Anovulation; Computer Simulation; Dehydroepiandrosterone; Dehydr | 1995 |
[Evaluation of hyperandrogenism: what levels?].
Topics: 17-alpha-Hydroxyprogesterone; Androgens; Androstenedione; Dehydroepiandrosterone; Female; Hirsutism; | 1995 |
Does hyperandrogenism explain lower in vitro fertilization (IVF) success rates in smokers?
Topics: Adult; Analysis of Variance; Androstenedione; Dehydroepiandrosterone; Estradiol; Female; Fertility; | 1996 |
Obesity and endocrine disorders in women taking valproate for epilepsy.
Topics: Adult; Body Weight; Carbamazepine; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Endocrine | 1996 |
Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity.
Topics: 17-alpha-Hydroxypregnenolone; 17-alpha-Hydroxyprogesterone; 17-Hydroxycorticosteroids; Adolescent; A | 1996 |
Different dysregulations in adrenal steroid biosynthesis as a prevalent cause of hyperandrogenism in women from southern Italy.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adul | 1997 |
Polycystic ovarian condition in the dehydroepiandrosterone-treated rat model: hyperandrogenism and the resumption of meiosis are major initial events associated with cystogenesis of antral follicles.
Topics: Androstenedione; Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Follicle Stimulati | 1997 |
Hyperinsulinemia and sex hormones in healthy premenopausal women: relative contribution of obesity, obesity type, and duration of obesity.
Topics: Adult; Androstenedione; Body Weight; C-Peptide; Dehydroepiandrosterone; Estradiol; Fasting; Female; | 1998 |
[Biochemical markers and methods to assess insulin resistance in normal, obese and hyperandrogenic women].
Topics: Adult; Biomarkers; Blood Glucose; Dehydroepiandrosterone; Female; Glucose Tolerance Test; Humans; Hy | 1997 |
Prevalence of 3beta-hydroxysteroid dehydrogenase-deficient nonclassic adrenal hyperplasia in hyperandrogenic women with adrenal androgen excess.
Topics: 17-alpha-Hydroxyprogesterone; 3-Hydroxysteroid Dehydrogenases; Adolescent; Adrenal Hyperplasia, Cong | 1999 |
Exploratory biochemical data analysis: a comparison of two sample means and diagnostic displays.
Topics: Acne Vulgaris; Computer Graphics; Data Display; Data Interpretation, Statistical; Dehydroepiandroste | 2001 |
Two hyperandrogenic adolescent girls with congenital portosystemic shunt.
Topics: Adolescent; Adrenocorticotropic Hormone; Androstenedione; Dehydroepiandrosterone; Female; Glucose To | 2001 |
Effect of low birth weight on adrenal steroids and carbohydrate metabolism in early adulthood.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Glands; Adult; Aging; Androstenedione; Carbohydrate Metabolism | 2001 |
Premature pubarche in girls is associated with functional adrenal but not ovarian hyperandrogenism.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Cortex; Androstenedione; Biomarkers; Case-Control Studies; Chi | 2002 |